Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:145935548" >
Subcutaneous daratu...
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
-
Iida, S (författare)
-
Ishikawa, T (författare)
-
Min, CK (författare)
-
visa fler...
-
Kim, K (författare)
-
Yeh, SP (författare)
-
Usmani, SZ (författare)
-
Mateos, MV (författare)
-
- Nahi, H (författare)
- Karolinska Institutet
-
Heuck, C (författare)
-
Qin, X (författare)
-
Parasrampuria, DA (författare)
-
Gries, KS (författare)
-
Qi, M (författare)
-
Bahlis, N (författare)
-
Ito, S (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-02-18
- 2021
- Engelska.
-
Ingår i: Annals of hematology. - : Springer Science and Business Media LLC. - 1432-0584 .- 0939-5555. ; 100:4, s. 1065-1077
- Relaterad länk:
-
https://link.springe...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had ≥ 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or were double refractory. Co-primary endpoints were overall response rate (ORR) and maximum trough concentration (Ctrough). Secondary endpoints included rates of infusion-related reactions, progression-free survival, and patient-reported satisfaction with therapy. Sixty-seven Asian patients (DARA SC, n = 30; DARA IV, n = 37) were randomized, including 42 Japanese patients (DARA SC, n = 18; DARA IV, n = 24). Comparable ORRs for DARA SC versus DARA IV were seen in the Asian cohort (66.7% vs 43.2%) and Japanese-only cohort (61.1% vs 54.2%), including patients weighing ≤ 65 kg. Similarity of Ctrough was seen in both Asian and Japanese-only cohorts; the ratio of the geometric mean of the Ctrough concentrations for DARA SC/DARA IV was 143.96% (90% confidence interval (CI), 112.03–185.00%) and 148.02% (90% CI, 113.32–193.34%), respectively. The Asian cohort (both treatment groups) and Japanese-only cohort (DARA SC group) experienced higher rates of grade 3/4 cytopenias compared with the global COLUMBA population, occurring predominantly in patients of low bodyweight; no patients discontinued treatment due to cytopenias. The Cancer Therapy Satisfaction Questionnaire results generally favored DARA SC. In the Asian and Japanese-only cohorts, DARA SC was comparable to DARA IV. The efficacy, pharmacokinetic, safety, and satisfaction results were generally consistent with the global COLUMBA population regardless of patient bodyweight. ClinicalTrials.gov Identifier: NCT03277105
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Iida, S
-
Ishikawa, T
-
Min, CK
-
Kim, K
-
Yeh, SP
-
Usmani, SZ
-
visa fler...
-
Mateos, MV
-
Nahi, H
-
Heuck, C
-
Qin, X
-
Parasrampuria, D ...
-
Gries, KS
-
Qi, M
-
Bahlis, N
-
Ito, S
-
visa färre...
- Artiklar i publikationen
-
Annals of hemato ...
- Av lärosätet
-
Karolinska Institutet